Next, we examined whether the blockade of TGF-β signaling could benefit the treatment of renal cell carcinoma using PFD, an approved anti-fibrotic drug by US FDA, which is proved to suppress TGF-β signaling in other cells. The gene discussed is TGFB1; the disease is renal cell carcinoma.